Pain Therapeutics公 PTIE 深 滬
等待開盤 10-29 09:30:00 美东时间
1.24
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 1.24
- 總市值 2066.00万
- 52周最高 2.99
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.76
- 委 比 0.00%
- 總股本 1666.13万
- 歷史最高 43.54
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.76
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch
Plus Therapeutics, Inc. expands its commercial readiness and manufacturing capabilities for CNS cancer diagnostics through the launch of CNSide Diagnostic LLC's CSF Tumor Cell Enumeration LDT. The company appoints Russ Havranek as Executive Vice President, Commercial and Corporate Strategy, and Daniel Ortega as Vice President, Development and Technical Operations, to drive growth. Key developments include state-of-the-art laboratory expansion in ...
10-21 11:30
PainReform Provides Business Update for the Six Months Ended June 30, 2025
PainReform Ltd. reported progress in its dual strategy to reformulate therapeutics and develop AI-driven solar technologies. The company completed a majority investment in LayerBio, acquiring its OcuRing™-K, a dropless cataract therapy targeting a $9B market. PainReform advanced PRF-110, showing early efficacy in postoperative pain, while spending on R&D fell to $0.3M. DeepSolar expanded with a Smart Energy Management app, joined NVIDIA's Connect...
10-01 13:27
Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
CNSide Diagnostics, a subsidiary of Plus Therapeutics, Inc., has signed a national agreement with UnitedHealthcare to provide the CNSide® Cerebrospinal Fluid Tumor Cell Enumeration test to over 51 million people in the U.S. The CNSide® CSF Assay Platform aids in rapid diagnoses, treatment monitoring, and guidance for patients with leptomeningeal metastases. Already, over 11,000 tests have been conducted at U.S. cancer institutions since 2020, ach...
09-25 11:30
Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT
Plus Therapeutics received a $1.9 million non-dilutive payment from the Cancer Prevention and Research Institute of Texas (CPRIT), part of a $17.6 million grant for its leptomeningeal cancer radiotherapeutic program. This is the second non-dilutive financing from CPRIT, following a $1.6 million payment in July 2025. The funding supports clinical development of REYOBIQ™ for the ReSPECT-LM trial and advances the CNSide LM diagnostic test. Plus Ther...
09-22 11:30
Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory
CNSide Diagnostics, a subsidiary of Plus Therapeutics, Inc., has received a CLIA certification from the Centers for Medicare & Medicaid Services (CMS) for its Houston-based lab. This certification is a crucial step toward broad U.S. market release of the CNSide CSF Assay Platform, meeting federal and state regulatory requirements. It enables the company to pursue state licensure, secure insurance coverage, and expand payment coding, supporting th...
09-18 11:30
Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases
Plus Therapeutics, Inc. announced positive results from the ReSPECT-LM Phase 1 trial of REYOBIQ for treating leptomeningeal metastases (LM). The study showed a clinical benefit rate over 75%, significant tumor cell reduction, and a favorable safety profile with no dose-limiting toxicities observed. Median overall survival was 9 months, compared to the typical 2-6 months for LM patients. Results support the recommended phase 2 dose of 44.1 mCi and...
08-18 11:30
PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System
PainReform Ltd. has acquired a majority stake in LayerBio Inc., a biotech company developing "dropless" solutions for ophthalmic surgery. The investment focuses on advancing LayerBio’s OcuRing™-K, a sustained-release intraocular ring designed to deliver anti-inflammatory and analgesic medication during cataract surgery, addressing patient compliance issues and reducing reliance on multiple medications. This transaction positions PainReform to add...
08-13 12:30
Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic
Houston-based Plus Therapeutics subsidiary CNSide Diagnostics will launch its CSF assay platform for detecting cancer metastases in the central nervous system in Texas in August 2025. The initial commercial focus will be on NCI-Designated Cancer Centers and large healthcare systems. The CNSide assay offers high sensitivity (92%) and specificity (95%), surpassing traditional CSF cytology methods. It has been used in over 11,000 tests since 2020 an...
07-31 11:30
Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference
HOUSTON, July 10, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. announced that its subsidiary, CNSide Diagnostics, will present two studies at the upcoming SNO/ASCO CNS Metastases Conference on August 14-16, 2025, in Baltimore, MD. The studies focus on the clinical utility of the CNSide CSF Assay Platform for detecting and quantifying tumor cells in cerebrospinal fluid (CSF) in patients with leptomeningeal disease. Priya Kumthekar, M.D., will ...
07-10 11:30
Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary
Plus Therapeutics, Inc. will commercially launch its CNSide CSF Assay Platform for diagnosing CNS metastases in the U.S. in late 2025, targeting a $6+ billion underserved market. The platform, which offers superior sensitivity (92%) and specificity (95%) compared to traditional methods, has been used in over 11,000 tests since 2020. The company plans rapid expansion across the U.S. and has secured payor agreements. Management will host a conferen...
06-26 11:30
